For the first time a treatment that corrects errors in a person's genetic code has been approved for commercial use in Europe.
The field of gene therapy has a simple aim, to correct the genetic code of people with genetic conditions, but it has been plagued with problems over the years. Some patients have developed leukaemia and in one US trial a teenage patient died.
Glybera, which is a gene therapy for a rare disease that leaves people unable to properly digest fats, has been given marketing authorisation by the European Commission. This means that it can be sold throughout the EU and the manufacturers, UniQure, say it will become available next year. Lipoprotein lipase deficiency, the disease in question, means that fat build-ups develop in the blood causing abdominal pain and life-threatening pancreatitis. At the moment the only way to manage the condition is by having a very low-fat diet. The new treatment works, as does every other gene therapy treatment, by using a virus to infect muscle cells with a working copy of the gene.
The CEO of UniQure, Jorn Aldag, said: "The final approval of Glybera from the European Commission marks a major step forward in making gene therapies available not only for lipoprotein lipase deficiency, but also for a large number of rare diseases with a very high unmet medical need." Also the company said it planned to apply for regulatory approval in the US and Canada, allowing the treatment to be given to more sufferers of the disease.
Hopefully this will now spur on more research into gene therapy and lead to new treatments that can treat a variety of genetic diseases, without the troubling side effects that have been seen in the past.
Jack
No comments:
Post a Comment